Pharmacy Times

MARCH 24, 2024

A pharmacist discusses the impact of comprehensive weight management with a shared decision making approach.

26

26

Express Pharma

JANUARY 2, 2024

It has been approved globally for the management of type 2 diabetes mellitus in adult patients in the US and the EU. Clinical trials on Indian adult patients with type 2 diabetes mellitus over a 24-week period have demonstrated Lirafit to be effective, safe and well-tolerated.

Diabetes 111

Diabetes Biosimilars 111

European Pharmaceutical Review

OCTOBER 30, 2023

A large-scale study led by researchers at the University of Cincinnati and New York’s largest health care provider, Northwell Health, suggests that metformin can help prevent or reduce weight gain in youth taking second-generation antipsychotics (SGAs) to treat bipolar disorder.

Diabetes 104

Diabetes 104

Pharmaceutical Technology

MARCH 29, 2023

Viking Therapeutics has announced the start of a Phase I clinical study to evaluate its dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist VK2735. Activating the GLP-1 receptor is known to reduce appetite and lower body weight.

Diabetes 105

Diabetes Dosage Labelling 105

ALiEM - Pharm Pearls

DECEMBER 22, 2023

She was unable to bear weight due to a 7/10 intensity pain on the anterior medial aspect of her right thigh that was worse with movement. Occult fractures of the proximal femur: imaging diagnosis and management of 82 cases in a regional trauma center. View other cases from this Clinical Image Series on ALiEM. World J Emerg Surg.

158

158

Express Pharma

OCTOBER 3, 2023

To maintain controlled distribution, the National Institute for Health and Clinical Excellence (NICE) will implement eligibility criteria, focusing on patients with comorbidities and specific BMI ranges. Wegovy will also be available for patients who are eligible for specialist weight management services with a BMI of 30–34.9

Diabetes 52

Diabetes 52

European Pharmaceutical Review

SEPTEMBER 8, 2023

Compared with semaglutide , insulin therapy or a placebo, tirzepatide demonstrated that 81 percent to 97 percent of people achieved better glucose control in clinical trials. There were also 54 percent to 88 percent of patients who reached a five percent or greater reduction in body weight.

Diabetes 101

Diabetes 101

RX Note

FEBRUARY 29, 2024

Management Ideally, the goal should be remission, but complete remission with the absence of clinical activity and no use of glucocorticoids or immunosuppressive therapy is rare. Mild symptoms can be managed with NSAIDs with or without other analgesics. Lifestyle modifications Rest and proper exercise to manage the fatigue.

52

52

Med Ed 101

MARCH 19, 2023

Tirzepatide is a newer medication that is likely to get significant use in Type 2 diabetes and weight management. With the help of a wonderful pharmacy student, we previously did a tirzepatide clinical breakdown which you can find here. Tirzepatide avoids many drug interactions because it does not get broken down by CYP enzymes.

Diabetes 52

Diabetes 52

ALiEM - Pharm Pearls

JUNE 1, 2023

Clinical pearl: Hepatic encephalopathy is a strong contraindication to phenobarbital [9, 10]. Management of Alcohol Withdrawal in the Emergency Department: Current Perspectives. The Emergency Medicine Management of Severe Alcohol Withdrawal. The Journal of Emergency Medicine. 2013;44(3):592-598.e2. doi:10.1016/j.jemermed.2012.07.056.

Inpatient 246

Inpatient Hospitals 246

pharmaphorum

FEBRUARY 8, 2022

NICE has backed use of the Wegovy (semaglutide) for people with a body mass index (BMI) of 35 kg/m2 or more and at least one weight-related ailment – such as high blood pressure, high cholesterol or diabetes – as part of a weight management programme involving exercise and a reduce-calorie diet.

Labelling 104

Labelling Diabetes 104

Fuld & Company Blog

MARCH 27, 2023

W eight loss industr y stakeholders brace for a revolution as Wegovy , Ozempic and other semiglutide s pick up steam A new market is emerging thanks to the introduction of a highly effective weight loss solution in the form of a handy injectable pen. Online pharmacies and weight loss websites are jumping on the sales bandwagon.

Diabetes 52

Diabetes Online Pharmacies Packaging Pharmaceutical Companies 52

STAT

MARCH 26, 2024

There were nearly 28,000 additional doses of pills for “self-managed” abortions in the six months after the fall of Roe, more than four times the number of pills per month that were reported before the decision. a decade after the chain announced it would implement a “No Antibiotics Ever” policy by 2019.

Drug Pricing 236

Drug Pricing Insurance Coverage and Processing Diabetes Pharmaceutical Companies 236

pharmaphorum

AUGUST 24, 2021

million in first-round financing, which it will use to scale up its clinical tool that it says helps people “prevent, manage and reverse type 2 diabetes.” change in HbA1c is considered clinically significant. Digital health startup Breathe Well-being has raised $5.5 That is a remarkable finding, considering a 0.5%

Diabetes 125

Diabetes 125

RX Note

APRIL 5, 2024

Over time, stretch marks lose their colour and become white or silvery in appearance (replaced by scar tissue). Causes If you develop stretch marks, you are most likely to do so during these times.

Mayo Clinic 52

Mayo Clinic 52

pharmaphorum

AUGUST 8, 2022

A study of a mobile health app used to support patients hospitalised with heart failure has concluded that it provided a modest improvement in quality-of-life scores, as well as better clinical outcomes. It can be bewildering for heart failure patients to implement the advice of their doctors, says Pattern Health.

Hospitals 145

Hospitals 145

Pharmaceutical Technology

MAY 9, 2023

Health Canada has approved Rhythm Pharmaceuticals’ IMCIVREE setmelanotide subcutaneous injection for use in weight management in adult and paediatric patients aged six years and above with Bardet-Biedl syndrome (BBS).

52

52

PharmD Live

APRIL 20, 2022

In June of 2021 FDA approved a new medication for weight loss called Wegovy. It’s the first GLP-1 agonist approved for weight loss since approving Saxenda (Liraglutide) in 2014. Semaglutide at a higher dose now is approved under the brand name Wegovy to assist patients with weight loss, regardless of type 2 diabetes.

Diabetes 52

Diabetes Hospitals 52

pharmaphorum

OCTOBER 16, 2020

The trial – run by Boehringer Ingelheim and Yale University – will test a smart bathroom scale device that has cardiac monitoring built in, as well as an app to help patients improve their diet and lose weight and a digital assistant designed to motivate them to actively manage their health. Perry Wilson.

Communication 119

Communication Hospitals 119

European Pharmaceutical Review

MARCH 24, 2023

In this Q&A, Dr Mansbach elaborates on how FGF21 analogues may work to address the liver manifestations, but also help manage the underlying causes of the disease. He also shares key data from the ongoing Phase IIb clinical trial, and discusses the broader challenges of developing novel therapies in the NASH space.

Drug Development 90

Drug Development 90

European Pharmaceutical Review

NOVEMBER 17, 2023

The European Commission has approved Ebglyss (lebrikizumab) for atopic dermatitis patients 12 years and older with a body weight of at least 40kg, who are candidates for systemic therapy. The Phase III clinical development programme, which involved some 1,300 patients, also evaluated the safety profile of lebrikizumab.

Hospitals 88

Hospitals 88

pharmaphorum

NOVEMBER 12, 2021

The CHMP recommended marketing authorisation for Wegovy (semaglutide) for chronic weight management in adults with obesity, and also in overweight adult patients with a weight-related risk factor such as high blood pressure, heart disease or type 2 diabetes. Subjects who received Wegovy lost an average of 12.4%

Diabetes 57

Diabetes 57

pharmacy mentor

JANUARY 15, 2024

New Pharmacy: Embracing digital advancements with electronic record-keeping, cloud-based storage, advanced integrative PMR systems , sophisticated websites and/or apps, digital communication with patients, adoption of multiple payment methods, and the implementation of Customer Relationship Management (CRM) systems.

Medical Records 52

Medical Records Data Entry Communication Medication Dispensing 52

Pharmaceutical Technology

MAY 24, 2023

Key opinion leaders (KOLs) interviewed by GlobalData have highlighted that despite Wegovy’s notable clinical benefits, the biggest disadvantage of this therapy is that people are unable to receive this treatment.

Diabetes 52

Diabetes 52

pharmaphorum

NOVEMBER 7, 2022

While investment in NASH has waned in the context of rigid histological endpoints and clinical setbacks, opportunities to target obesity and other metabolic disorders through the lens of a holistic approach to metabolic syndrome are exploding. Take a look at the complete program here.

Drug Development 52

Drug Development 52

Pharmaceutical Technology

MAY 11, 2023

The collaboration will see Bicycle use its phage platform to discover and develop bicyclic peptides while Bayer will fully fund and manage further preclinical and clinical development, manufacturing and commercialisation aspects.

64

64

pharmaphorum

OCTOBER 8, 2021

Twin Health has published interim results from a randomised clinical trial in 33 diabetic subjects to back up its claims. The subjects using the digital therapeutic also had an average weight reduction of more than 9 kg over the course of the study and improvements in liver function scores. from a baseline average of 8.7.

Diabetes 143

Diabetes 143

RX Note

JUNE 10, 2023

As a result of this shift, sodium glucose co-transporter 2 (SGLT-2) inhibitors, such as canagliflozin, dapagliflozin and empagliflozin, have emerged as a key player for managing type 2 diabetes. reduction in HbA1c Effect on both fasting and postprandial glucose concentrations Promote weight loss. Expected Benefits Lower blood glucose.

Diabetes 52

Diabetes Labelling Hospitals 52

RX Note

FEBRUARY 2, 2023

Clinical Presentation Pulmonary TB is characterized by its slow onset and initial mild symptoms. Other symptoms of the condition are malaise, fever, night sweats and weight loss. NOTE: Medication dose requires recalculation every 2 to 4 weeks as children gain weight rapidly, particularly in neonates and young children.

Immunity 52

Immunity Immunization Hospitals 52

pharmaphorum

OCTOBER 30, 2020

Novo Nordisk’s Saxenda has been recommended by NICE as a treatment for obesity, ending a 10-year drought in new drug therapies for weight management. It will be prescribed in secondary care, by a specialist multidisciplinary tier 3 weight management service.

Diabetes 65

Diabetes 65

pharmaphorum

MARCH 4, 2022

Sylvest told the meeting that “Wegovy has the potential to unlock the obesity market,” as it its clinical profile is encouraging more people with obesity and their doctors to consider drug therapy as part of a weight management programme, and more payers to cover the cost. US sales of the pair same in at 4.9

62

62

Pharmaceutical Technology

APRIL 13, 2023

Key opinion leaders (KOLs) interviewed by GlobalData highlighted the need for safer and more effective therapies with fewer side effects that would be suitable for the treatment of obesity, particularly for the management of weight loss following cessation of treatment.

Labelling 52

Labelling Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

RX Note

SEPTEMBER 10, 2023

CKD Staging Staging of CKD is done according to Cause of disease 6 categories of GFR (G stages) 3 categories of albuminuria (A stages) The purpose of CKD staging is to guide management, including stratification of risk for progression and complications of CKD. Renal function trajectory pattern.

Diabetes 52

Diabetes Dosage Communication 52

FADIC

OCTOBER 20, 2023

Medication Therapy Management in geriatric Medication Therapy Management (MTM) Is a service provided typically by pharmacists that aims to improve outcomes by helping people to better understand their health conditions and the medications used to manage them. – patients record what they did and when they took action.

Health and Personal Care Stores 52

Health and Personal Care Stores Documentation Medication Therapy Management (MTM) Medical Records 52

pharmaphorum

MAY 19, 2021

While clinical trials are often designed with regulators in mind, and the efficacy and safety data they generate may be sufficient to obtain regulatory approval, this data alone is rarely sufficient to convince payers it is a product worth investing in.

Communication 70

Communication 70

RX Note

JUNE 18, 2023

It does not cause weight gain or hypoglycaemia when given alone. The most common adverse effects of sulfonylureas are weight gain and hypoglycaemia. Meglitinides may cause a range of side effects , most commonly hypoglycaemia, weight gain, visual disturbances, abdominal pain, diarrhoea, constipation, nausea and vomiting.

Diabetes 52

Diabetes Dosage Hospitals 52

pharmaphorum

MARCH 24, 2022

GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds.

Compounding 104

Compounding Immunity Immunization Drug Development 104